#ES­MO17: Bris­tol-My­ers posts da­ta on an up­set check­point com­bo vic­to­ry in front­line kid­ney can­cer

Madrid — There may be five PD-(L)1 drugs on the mar­ket, but they’re still con­tin­u­ing to pro­duce sur­pris­ing re­sults in clin­i­cal tri­als.

The lat­est up­set is a win for Bris­tol-My­ers Squibb. Af­ter fail­ing to hit its marks on pro­gres­sion-free sur­vival, a com­bi­na­tion of Op­di­vo and Yer­voy re­duced the risk of death by 37% com­pared to Pfiz­er’s stan­dard-of-care suni­tinib among in­ter­me­di­ate- and poor-risk kid­ney can­cer pa­tients. The com­bo al­so kicked in with an im­proved over­all sur­vival rate — not yet ful­ly de­ter­mined — ac­cord­ing to the lat­est da­ta for CHECK­MATE-214 re­leased at ES­MO on Sun­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER